SCAP

Grifols announces positive topline phase 3 fibrinogen clinical trial results

Retrieved on: 
Wednesday, February 14, 2024

AFD, which typically occurs during surgical procedures when there’s insufficient fibrinogen to arrest bleeding, is commonly treated with cryoprecipitate (a plasma extract) or fresh frozen plasma, both containing fibrinogen.

Key Points: 
  • AFD, which typically occurs during surgical procedures when there’s insufficient fibrinogen to arrest bleeding, is commonly treated with cryoprecipitate (a plasma extract) or fresh frozen plasma, both containing fibrinogen.
  • Fibrinogen, a plasma protein produced in the liver, plays a key role in stopping blood loss and in wound healing.
  • “The positive results for Biotest’s fibrinogen are an important milestone and strengthen a Grifols innovation strategy that’s diversified across plasma and non-plasma, balanced between internal and external investments, and includes both shorter- and longer-term development cycles,” said Victor Grifols Deu, Grifols Chief Operating Officer.
  • The acquisition of Biotest has significantly reinforced Grifols’ access to plasma, as well as the company’s pipeline and sales presence.

Infrastructure Capital Advisors Declares Its Monthly Dividends: The InfraCap Small Cap Income ETF (SCAP) and InfraCap Equity Income Fund ETF (ICAP)

Retrieved on: 
Friday, January 26, 2024

The InfraCap Small Cap Income ETF (NYSE Arca: SCAP) (the “Fund”) has declared a monthly distribution of $0.175 per share ($2.10 per share on an annualized basis).

Key Points: 
  • The InfraCap Small Cap Income ETF (NYSE Arca: SCAP) (the “Fund”) has declared a monthly distribution of $0.175 per share ($2.10 per share on an annualized basis).
  • The InfraCap Equity Income Fund ETF (NYSE Arca: ICAP) (the “Fund”) has declared a monthly distribution of $0.180 per share ($2.16 per share on an annualized basis).
  • Infrastructure Capital Advisors expects to declare future distributions on a monthly basis.
  • Preferred Stock ETF (NYSE Arca: PFFA), InfraCap REIT Preferred ETF (NYSE Arca: PFFR), InfraCap MLP ETF (NYSE Arca: AMZA), and the InfraCap Equity Income Fund ETF (NYSE Arca: ICAP).

EQS-News: Biotest expands its clinical development program for trimodulin to patients with community-acquired pneumonia (CAP)

Retrieved on: 
Saturday, December 30, 2023

Biotest announced this week that the first hospitalized patient with Community-Acquired Pneumonia (CAP) has been treated in the multinational phase III TRICOVID trial.

Key Points: 
  • Biotest announced this week that the first hospitalized patient with Community-Acquired Pneumonia (CAP) has been treated in the multinational phase III TRICOVID trial.
  • The TRICOVID trial was already enrolling hospitalized patients with COVID-19 who require supplemental oxygen due to the severity of their disease.
  • However, trimodulin is not only expected to be effective in treatment of COVID-19 patients.
  • This further expedites the development of trimodulin as potential new treatment option for a broad population of hospitalized patients with CAP”, emphasized Dr Thomas Häder, Head of Clinical Strategy and Development at Biotest.

Infrastructure Capital Advisors Launches Its Newest ETF: the InfraCap Small Cap Income ETF (SCAP)

Retrieved on: 
Tuesday, December 12, 2023

Infrastructure Capital Advisors (“InfraCap”), a leading provider of investment management solutions designed to meet the needs of income-focused investors, is today announcing the launch of the latest addition to the firm’s lineup of Exchange-Traded Funds (“ETFs”): the InfraCap Small Cap Income ETF (NYSE Arca: SCAP).

Key Points: 
  • Infrastructure Capital Advisors (“InfraCap”), a leading provider of investment management solutions designed to meet the needs of income-focused investors, is today announcing the launch of the latest addition to the firm’s lineup of Exchange-Traded Funds (“ETFs”): the InfraCap Small Cap Income ETF (NYSE Arca: SCAP).
  • “Small-cap stocks are trading at historically low prices and may be poised for a bounce back year in 2024.
  • We believe that substantial alpha can be added through active management of the less efficient small cap sector,” said Hatfield.
  • Preferred Stock ETF (NYSE Arca: PFFA), InfraCap REIT Preferred ETF (NYSE Arca: PFFR), InfraCap MLP ETF (NYSE Arca: AMZA), and the InfraCap Equity Income Fund ETF (NYSE Arca: ICAP).

EQS-News: Biotest’s Trimodulin shows reduced mortality in patients with severe community-acquired pneumonia through rapid normalisation of inflammation

Retrieved on: 
Thursday, December 14, 2023

The article describes new mechanisms by which trimodulin supports the immune system in patients with severe Community-Acquired Pneumonia (sCAP).

Key Points: 
  • The article describes new mechanisms by which trimodulin supports the immune system in patients with severe Community-Acquired Pneumonia (sCAP).
  • One major characteristic of sCAP patients is that their immune system becomes dysregulated, which results in inflammation.
  • The results reported, support the currently ongoing investigation of trimodulin in artificial ventilated patients with sCAP with evidence of significant inflammation (ESsCAPE trial).
  • In addition, trimodulin is currently also in development for the treatment of hospitalized, oxygen-supported patients with non-severe CAP, including COVID-19 (TRICOVID trial).

EQS-News: Biotest increases EBIT to Euro 125.4 million in the first nine months of 2023

Retrieved on: 
Tuesday, November 7, 2023

This development is due to the higher income taxes in connection with the earnings effect from technology disclosure and development services.

Key Points: 
  • This development is due to the higher income taxes in connection with the earnings effect from technology disclosure and development services.
  • This is equivalent to earnings per ordinary share of € 2.22 compared with € - 0.87 in the same period of the previous year.
  • In September 2023, Biotest also reached an important milestone in the marketing authorisation process for Yimmugo in the USA.
  • This revenue growth is enabled by the commissioning of the Yimmugo® production facility within Biotest Next Level.

Starbucks Raises the Bar With Industry-Leading Employee Benefits, Outperforming Competitors

Retrieved on: 
Monday, November 6, 2023

“Investing in our partners is what drives our success,” said Sara Trilling, executive vice president and president of Starbucks North America.

Key Points: 
  • “Investing in our partners is what drives our success,” said Sara Trilling, executive vice president and president of Starbucks North America.
  • And an important way we do this is by investing in our partners’ journey, to bridge to a better future at Starbucks and beyond.
  • Highlights of partner investments include:
    Vacation Accrual: With every cup, with every conversation, with every community – Starbucks nurtures the limitless possibilities of human connection.
  • Introduction of First-Ever North America Barista Championship: Starbucks partners take pride in their craft and have fun while doing it.

EQS-News: Biotest AG: Biotest treats first patient with severe community-acquired pneumonia in phase III trial with trimodulin

Retrieved on: 
Saturday, September 16, 2023

Biotest announced today that the first patient with sCAP has been treated in the phase III ESsCAPE trial in an intensive care unit.

Key Points: 
  • Biotest announced today that the first patient with sCAP has been treated in the phase III ESsCAPE trial in an intensive care unit.
  • This multinational phase III clinical trial is expected to enrol approximately 590 adult patients with severe Community Acquired Pneumonia (sCAP).
  • In the CIGMA trial a subgroup of patients with evidence of severe inflammation showed an encouraging reduction in the mortality rate when treated with trimodulin.
  • In addition to clinical development for sCAP, trimodulin is also currently in development for the treatment of COVID-19.

NCMS Report Establishes Road Map for Accelerating Transition from Gas-Powered to Electric Vehicles

Retrieved on: 
Thursday, September 14, 2023

To reduce the United States’ generation of CO-2 emissions, Americans in both private and public sectors have been working to increase the adoption of electric vehicles (EVs).

Key Points: 
  • To reduce the United States’ generation of CO-2 emissions, Americans in both private and public sectors have been working to increase the adoption of electric vehicles (EVs).
  • A recent NCMS initiative sought solutions to these issues by researching vehicle electrification and potential crossovers between the civilian and military domains.
  • The team completed a comprehensive investigation and designed a road map for transitioning from gas-powered vehicles to fully electric vehicles.
  • The study recommends a gradual transition, beginning with parallel hybrid electric (HE) vehicles with an upgradeable configuration to AE.

OSC Edge Introduces OPTICA Security: Transforming DoD Compliance Management with User-Centric Innovation

Retrieved on: 
Tuesday, August 15, 2023

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230815293259/en/
    OSC Edge proudly presents a groundbreaking advancement in compliance management with the launch of OPTICA Security.
  • (Graphic: Business Wire)
    OPTICA Security Redefines Compliance Management:
    User-Centric Approach: OPTICA Security's state-of-the-art features and thoughtfully designed interface streamline compliance management, presenting a new paradigm in DoD compliance practices.
  • "We are thrilled to unveil OPTICA Security, a game-changing solution that redefines compliance management in the DoD landscape," says Tiffany Bailey, President & Chief Executive Officer of OSC Edge.
  • Experience the future of DoD compliance management with OPTICA Security.